Starpharma Holdings マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Cheryl Maley

最高経営責任者

AU$475.8k

報酬総額

CEO給与比率	51.3%
CEO在任期間	less than a year
CEOの所有権	0.03%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	2.9yrs

経営陣の近況

Recent updates

CEO報酬分析

Starpharma Holdings の収益と比較して、Cheryl Maley の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	AU$476k	AU$244k	-AU$8m

報酬と市場: Cherylの総報酬 ($USD 311.92K ) は、 Australian市場 ($USD 299.68K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Cherylの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Cheryl Maley (55 yo)

less than a year

在職期間

AU$475,764

報酬

Mrs. Cheryl Maley, B.Sc, DipEd, MBA, GAICD, serves as Chief Executive Officer, Managing Director and Director of Starpharma Holdings Limited since January 8. 2024. She served as Non-Executive Director of C...

取締役

名称	ポジション	在職期間	報酬	所有権
Cheryl Maley	CEO, MD & Director	less than a year	AU$475.76k	0.030% A$ 12.3k
Robert Thomas	Non-Executive Chairman	10.9yrs	AU$136.95k	0.66% A$ 269.5k
David McIntyre	Non-Executive Director	4.7yrs	AU$81.00k	0.10% A$ 41.4k
Jeff Davies	Non-Executive Director	2.6yrs	AU$75.00k	0.22% A$ 91.1k
Russell Basser	Non-Executive Director	1.8yrs	AU$77.04k	0.065% A$ 26.6k
Lynda Cheng	Independent Non-Executive Director	3.3yrs	AU$88.54k	0.041% A$ 16.7k

2.9yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: SPLの取締役会は経験豊富ではない ( 2.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Starpharma Holdings マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Non-Executive Director recently bought AU$80k worth of stock

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Recent updates

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary

Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia

Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca

Starpharma Holdings Limited Announces Management Changes

Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022

Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO

Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model

Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray

Starpharma Holdings Limited Appoints Jeff Davies as Director

Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK

Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron

Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel

Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

Starpharma Releases New Data About SPL7013

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus

Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model

Starpharma Signs DEP ADC Research Agreement with MSD

Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion

New 90-day high: AU$1.79

New 90-day high: AU$1.66

New 90-day low: AU$1.27

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Announces SPL7013 Shows Potent Antiviral Activity in RSV Expanding Use for Nasal Spray

Starpharma Holdings Limited announced that it has received AUD 45 million in funding

Starpharma Holdings Limited announced that it expects to receive AUD 45 million in funding

Starpharma Holdings Limited Announces That Australia Therapeutic Goods Administration Approves Expansion of the Marketing Authorisation for Vivagel® Bv

New 90-day high - AU$1.73

Earnings released

New 90-day high - AU$1.28